Company profile for Rain Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic success for patients by focusing on genetic biomarkers that may predict optimal therapeu...
Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic success for patients by focusing on genetic biomarkers that may predict optimal therapeutic strategies, and (2) pursue biomarker-based trial designs of limited size that enable rapid decision-making and redirecting of strategy when needed, minimizing expense and preserving capital resources.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
8000 Jarvis Ave Suite 204 Newark, CA 94560
Telephone
Telephone
510-953-5559
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240126877395/en

BUSINESSWIRE
26 Jan 2024
Rain ends stormy year by opting to be acquired by Pathos AI
Rain ends stormy year by opting to be acquired by Pathos AI

14 Dec 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/rain-ends-stormy-year-layoffs-opting-be-acquired-pathos-ai-over-concentra#:~:text=Rain%20ends%20stormy%20year%20of,by%20Pathos%20AI%20over%20Concentra&text=After%20a%20year%20of%20layoffs,suitable%20buyer%20has%20paid%20off.

James Waldron FIERCE BIOTECH
14 Dec 2023

https://www.globenewswire.com//news-release/2023/12/13/2795922/0/en/Rain-Oncology-Enters-into-Agreement-to-be-Acquired-by-Pathos-AI-for-1-16-in-Cash-per-Share-Plus-Contingent-Value-Rights.html

GLOBENEWSWIRE
13 Dec 2023

https://www.globenewswire.com//news-release/2023/11/09/2777781/0/en/Rain-Oncology-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
09 Nov 2023
Concentra offers to buy troubled Rain Oncology
Concentra offers to buy troubled Rain Oncology

16 Oct 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/rain-oncology-latest-troubled-biotech-receive-acquisition-offer-concentra

James Waldron FIERCE BIOTECH
16 Oct 2023

https://www.globenewswire.com//news-release/2023/10/16/2760579/0/en/Rain-Oncology-Confirms-Receipt-of-Unsolicited-Proposal-from-Concentra-Biosciences.html

GLOBENEWSWIRE
16 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty